A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 347-351

  Smit, E F ^a,b   Fokkema, E ^a   Biesma, B ^b   Groen, H J M ^a   Snoek, W ^c   Postmus, P E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Early relapse; Small cell lung cancer

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

EID: 0031985696     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.54     Document Type: Article

References (27)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA and Arbuck SG (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 13: 2056-2065
2. Andersen M, Kristjansen PEG and Hansen HH (1990) Second-line chemotherapy in small-cell lung cancer. Cancer Treat Rev 17: 427-436
3. Carbone D and Kratzke R (1996) RB1 and P53 genes. In Lung Cancer: Principles and Practice, Pass HI, Mitchell JB, Johnson DH and Turissi AT (eds), pp. 107-121. Lippincott: Philadelphia.
4. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L and Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097
5. Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH (1995) Phase II study of Paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1430-1435
6. Giaccone G (1989) Second line chemotherapy in SCLC. Lung Cancer 5: 207-213
7. Grant SC, Gralla RJ, Kris MG, Orazem J and Kitsis EA (1992) Single agent chemotherapy trials in small-cell lung cancer 1970-1990: the case for studies in previously treated patients. J Clin Oncol 10: 484-498
8. Hainsworth JD, Stroup SL and Greco FA (1996) Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer 77: 2458-2463
9. Hainsworth JD, Gray JR, Hopkins LG, Thomas M, Patton J, Kalman LA and Greco FA (1997) Paclitaxel (1-hour infusion) carboplatin and extended schedule etoposide in small cell lung cancer (SCLC): a report on 117 patients (pts) treated by the Minnie Pearl Cancer Research Network (abstract). Proc Am Soc Clin Oncol 16: 1623
10. Hawkins DS, Demers GW and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898
11. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441
12. Jekunen AP, Christen RD, Shalinsky DR and Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299-306
13. Kirschling RJ, Jung SH and Jett JR (1994) A phase II trial of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer (abstract). Proc Am Soc Clin Oncol 13: 326
14. Lai SI, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K and Gazdar AF (1989) MDRI gene expression in lung cancer. J Natl Cancer Inst 81: 1144-1147
15. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
16. Moscow JA, Schneider E and Cowan KH (1996) In Cancer Chemotherapy and Response Modifiers, Pinedo HM, Longo DL and Chabner BA (eds), pp. 120-121. Elsevier: Amsterdam
17. Nair S, Marschke R, Grill J, Sloan J, Tazelaar H, Drevyanko T, Michalak J and Marks R (1997) A phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC) (abstract). Proc Am Soc Clin Oncol 16: 1629
18. Postmus PE, Berendsen HH, van Zandwijk NH, Splinter TAW, Burghouts JThM, Bakker W and the EORTC Lung Cancer Cooperative Group (1987). Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy Eur J Cancer Clin Oncol 23: 1409-1411
19. Postmus PE, Smit EF, Kirkpatrick A and Splinter TAW (1993) Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A: 204-207
20. Rowinsky EK, Eisenhauer EA, Chaudry V, Arbuck SG and Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20 (suppl. 3):1-15
21. Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1004-1014
22. Ruckdeschel J, Wagner H and Williams L (1994) Second-line chemotherapy for resistant, metastatic non-small cell lung cancer: the role of Taxol (abstract). Proc Am Soc Clin Oncol 13: 357
23. Safran H, King T, Choy H, Gollerheri A, Kwakwa H, Lopez F, Cole B, Myers J, Tarpey J and Rosmarin A (1996) p53 Mutatations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 78: 1203-1210
24. Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667
25. Smit EF, Berendsen HH, de Vries EGE, Mulder NH and Postmus PE (1989) A phase II study of carboplatin and vincristine in previously treated patients with small cell lung cancer. Cancer Chemother Pharmacol 25: 202-204
26. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto M, Hayn R and Arbuck SG (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute treatment referral centre 9103. J Clin Oncol 11: 2405-2410
27. Wahl AF, Donaldson KL, Fairchield C, Lu FY, Foster SA, Demers GW and Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79